Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05HFW
|
|||
| Former ID |
DNC014670
|
|||
| Drug Name |
CENTAUREIDIN
|
|||
| Synonyms |
Centaureidin; Desmethoxycentaureidine; 17313-52-9; 5,7,3'-Trihydroxy-3,6,4'-trimethoxyflavone; NSC-106969; UNII-548R7290J9; CHEMBL77552; MLS002701956; CHEBI:69356; 548R7290J9; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,6-dimethoxy-4H-chromen-4-one; centaureidine; NSC106969; NSC 106969; AC1NSTGP; SCHEMBL9953; cid_5315773; DTXSID50169530; MolPort-023-274-268; ZINC3871987; ZINC03871987; LMPK12113000; BDBM50064891; quercetagetin 3,6,4'-trimethyl ether; AKOS027326559; MCULE-7507998415; SMR001565538; 6-hydroxyquercetin 3,6,4''-trimethyl
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H16O8
|
|||
| Canonical SMILES |
COC1=C(C=C(C=C1)C2=C(C(=O)C3=C(O2)C=C(C(=C3O)OC)O)OC)O
|
|||
| InChI |
1S/C18H16O8/c1-23-11-5-4-8(6-9(11)19)16-18(25-3)15(22)13-12(26-16)7-10(20)17(24-2)14(13)21/h4-7,19-21H,1-3H3
|
|||
| InChIKey |
BZXULYMZYPRZOG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 17313-52-9
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:69356
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tubulin (TUB) | Target Info | Inhibitor | [1] |
| Tubulin beta (TUBB) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Phagosome | |||
| Gap junction | ||||
| Pathogenic Escherichia coli infection | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| EGFR1 Signaling Pathway | ||||
| Panther Pathway | Cytoskeletal regulation by Rho GTPase | |||
| Huntington disease | ||||
| Reactome | Regulation of PLK1 Activity at G2/M Transition | |||
| Loss of Nlp from mitotic centrosomes | ||||
| Recruitment of mitotic centrosome proteins and complexes | ||||
| Loss of proteins required for interphase microtubule organization?from the centrosome | ||||
| Anchoring of the basal body to the plasma membrane | ||||
| WikiPathways | Parkin-Ubiquitin Proteasomal System pathway | |||
| Pathogenic Escherichia coli infection | ||||
| Mitotic G2-G2/M phases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Structure-activity requirements for flavone cytotoxicity and binding to tubulin. J Med Chem. 1998 Jun 18;41(13):2333-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.